Screening for the Hypoglycaemic Potentials of the Extract of Vernonia amyggalina

Similar documents
Effect of Coccinia indica on Blood Glucose Levels in Alloxan-induced Diabetic Mice. Kathryn Niedzielski Advisor: Dr. Linda Swift

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

Causes, incidence, and risk factors

2. What Should Advocates Know About Diabetes? O

What is Type 2 Diabetes?

Understanding Diabetes

DIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY

LESSON TWO: COMPARE AND CONTRAST TYPE 1 AND TYPE 2 DIABETES

Dietfree-Good News for Diabetics

X-Plain Diabetes - Introduction Reference Summary

High Blood Sugar. Printable Materials

Background (cont) World Health Organisation (WHO) and IDF predict that this number will increase to more than 1,3 million in the next 25 years.

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.

Understanding Diabetes

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Diabetes Mellitus: Type 1

Blood Glucose Management

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria

Welcome to Diabetes Education! Why Should I Take Control of My Diabetes?

Diabetes means you have too much sugar in

X-Plain Hypoglycemia Reference Summary

SCHOOL DISTRICT #22 VERNON DIABETES POLICY

What is diabetes? Diabetes is a condition which occurs as a result of problems with the production and supply of insulin in the body.

1333 Plaza Blvd, Suite E, Central Point, OR *

Diabetes Fundamentals

Diabetes mellitus. Lecture Outline

Steroid Induced Diabetes

A list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products

Diabetes. Emergency Checklists. From A Child in Your Care Has Diabetes. A Collection of Information. Copyright 2005 by Elisa Hendel, M.Ed.

Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?

Type 1 Diabetes. Pennington Nutrition Series. Overview. About Insulin

Anchor Bay School District Diabetic Medical Care Plan. Student Name Date Grade Teacher

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Diabetes. Patient Education. What you need to know. Diabetes Facts. Improving Health Through Education. What is Diabetes?

Borgess Diabetes Center PATIENT REGISTRATION/DEMOGRAPHICS

A prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India

The Family Library. Understanding Diabetes

The Diabetes Epidemic

Type 2 diabetes Definition

Diabetes. Supporting Disabled Members in the Workplace. This short factsheet has been developed to help reps who are supporting members with diabetes.

Type 2 Diabetes. What is diabetes? Understanding blood glucose and insulin. What is Type 2 diabetes? Page 1 of 5

Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment

Introduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.

THE EFFECT OF SODIUM CHLORIDE ON THE GLUCOSE TOLERANCE OF THE DIABETIC RAT*

Section 504 Plan (pg 1 of 8)

written by Harvard Medical School Insulin Therapy Managing Your Diabetes

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

DIABETES. Eyes, Heart, Nerves, Feet, and Kidneys.

Section 5: Type 2 Diabetes

Take Charge of Your Diabetes

Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c

Type 2 Diabetes. Type 1 Diabetes. What is Diabetes? Diabetes during Pregnancy Very Thirsty Very Tired

Data Mining On Diabetics

Insulin: A Practice Update. Department of Nursing Staff Development Elizabeth Borgelt, MS, RN

Diabetes at the End of Life. Dr David Kerr MD Bournemouth Diabetes and Endocrine Centre

Diabetes for CNAs. This course has been awarded two (2.0) contact hours. This course expires on January 31, 2017.

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

HUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100)

Types of insulin and How to Use Them

Diabetes in the Long Term Care Setting: Advantages of Basal Insulin Therapy and Insulin Pen Devices

Diabetes Mellitus in Dogs

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE

Kansas Behavioral Health Risk Bulletin

Diet and haemodialysis

Insulin-Treated Diabetes. Guidelines for assessment of fitness to work as Cabin Crew

A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes

BLOOD GLUCOSE MONITORING MEDICATION

Myth vs. Reality: Diabetes Related

Owner Manual. Diabetes in Dogs. Simplifying small animal diabetes

Lincoln Memorial University Department of Nursing Nursing 124/125 Spring Semester 2005

Statistics of Type 2 Diabetes

Gestational diabetes. Information to help you stay healthy during your pregnancy. What is gestational diabetes?

Skills Standards ADVANCED CMA: INSULIN ADMINISTRATION OD68609 MEETS OSDH NURSE AIDE REGISTRY CERTIFICATION REQUIREMENTS

Chapter 2 What Is Diabetes?

Calculating Insulin Dose

GLUCOSE TOLERANCE (FOR DIABETESMELLITUS)- NON-PREGNANT ADULT/CHILDREN (Under 18 years old) (OGTT)

Employment Considerations for People who have Diabetes

Diabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e

Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT

HOW TO CARE FOR A PATIENT WITH DIABETES

Medical Assistant s Diabetes Survey

Healthy Weight Loss Program

DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa

Insulin Treatment. J A O Hare. Bones, Brains & Blood Vessels

Diabetes Mellitus Type 2

Surgery and Procedures in Patients with Diabetes

Diabetes and the Workplace

New Onset Diabetes After Transplant (NODAT)

Nige g ri e an a N at a ional a Antimal a ari a a Tre re t a men e t g ide d l e ines

Managing Diabetes in the School Setting. Alabama State Department of Education Alabama Board of Nursing

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Type 2 Diabetes Type 2 Diabetes

Understanding and Managing Type 2 Diabetes

University College Hospital. Sick day rules insulin pump therapy

INJEX Self Study Program Part 1

Feeling Better, Living Healthier With Diabetes

Objectives. Clinical Impact of An Inpatient Diabetes Care Model. Impact of Diabetes on Hospitals. The Nebraska Medical Center Stats 6/5/2014

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Lab: Graphing Activities TOTTEN

Transcription:

Ethnobotanical Leaflets 14: 759-65. 2010. Screening for the Hypoglycaemic Potentials of the Extract of Vernonia amyggalina T. R. Fasola 1, P.C. Okeocha 1 and A. Odetola 2 1 Department of Botany and Microbiology, Faculty of Science, University of Ibadan, Ibadan, Nigeria 2 Department of Biochemistry, Faculty of Pharmacy, University of Ibadan Ibadan, Nigeria E-mail: fasolatr@yahoo.com Issued: July 1, 2010 Abstract This work evaluates the hypoglycemic effect of Vernonia amygdalina on alloxan induced diabetic rats. Different doses of the aqueous leaf extract of Vernonia amygdalina (50mg/kg, 100mg/kg, 200mg/kg and 400mg/kg) were administered to alloxan induced diabetic rats under experimental conditions. The mean fasting blood sugar levels of the groups of diabetic rats increased significantly as it rose from basal blood sugar levels (mg/dl) of 38.0, 39.2, 35.2 and 35.8 to fasting blood sugar levels (mg/dl) of 277.6, 284.8, 256.4 and 265.6. The findings showed that there is a dose dependent reduction in fasting blood sugar in alloxan induced diabetic rats after treatment to 167.5mg/dl, 140.8mg/dl, 104.2mg/dl and 80.4mg/ dl respectively. Key words: Vernonia amygdalina, ethnomedicine, diabetes, alloxan. Introduction Diabetes mellitus is a diseased condition characterized by high glucose levels caused by an absolute or relative deficiency of insulin, a special sugar regulatory hormone produced by the pancreas, a gland in the body. It can be defined on the basis of laboratory findings as a fasting venous plasma concentration greater than 140mg/dl or 210mg/dl two hours after a carbohydrate meal or to two hours after the oral ingestion of the equivalent of 75mg of glucose. The disease (DM) is prevalent all over the world. It affects 11-20% of the European and United States of American white population. The highest risk was found in Pima Indians of Arizona and in the urbanized Micronesians of Nauru where up to one half of the population had diabetes (Kings and Rewers, 1991). DM can affect any age, sex, race or socioeconomic group. It was generally considered as disease of the developed countries but recent trends show that it is fast becoming a third world problem (Kings and Rewers, 1991). It has been found that 1-2.6% of the Nigerian population has DM (Kings and Rewers, 1991, Akinkugbe, 1992). The causes of DM include poor diet, obesity, environmental factors, hereditary factors and drug

usage and symptoms are increased urine production, increased thirst, and sugar in blood, excessive eating, loss of water and loss of memory. Complications of DM include damage to the kidneys, impaired vision, hardening and blockage of blood vessels, infections and impotence (Famuyiwa et al,, 1988). The advantages of medicinal plants over orthodox medicine are cheapness, relative availability, ease of preparation and absence of serious side effects..it has been estimated that in Nigeria, 80% of rural people depend on herbs for the treatment of various diseases. Extracts of leaves of Vernonia amygdalina have been found to possess antimalarial activity against plasmodium (Masaba 2000, Abosi and Roseroka 2003) and active against sexually transmitted diseases (Kambizi and Afolayan, 2001). Chewing sticks of V. amygdalina has been found to have antibacterial activity (Taiwo et al., 1999) and water soluble anti cancer agents have been discovered from the plant (Izevbigie, 2003). This study was undertaken to determine the hypoglycemic effect of Vernonia amygdalina leave extract. Materials and Methods Materials Fresh plants of Vernonia amygdalina were obtained from the International Institute of Tropical Agriculture (IITA), Ibadan, Nigeria. The identification of the plant was carried out at the Herbarium of the Department of Botany and Microbiology, University of Ibadan, Ibadan, Nigeria. The leaves of the plant were air dried in a shade and later grounded to a powdery form using a blender. 1g of the powdered herb was soaked in 100ml of distilled water to produce a concentration of 10mg/ml of the aqueous extract used for the experiment. The soaking was done overnight (twelve hours) in order to get the aqueous extract. Experimental animals Thirty healthy rats weighing between 150g and 250g were obtained from the Veterinary Physiology Animal House, University of Ibadan, Ibadan. Nigeria. Animal feeds were obtained from Ladokun Feed Mill Nigeria Limited, Ibadan. Nigeria. Alloxan Ten percent alloxan dissolved in physiological saline was used to induce the diabetic condition in the diabetic rats. This was by weighing 10g of fresh samples of alloxan on a Mettler s balance and dissolving in 100ml of 0.15M physiological saline solutions. The dose administered was a standard dose of 100mg/kg weight of the rats. The general formula stated below was used to obtain the actual volume of the drug to be administered: Volume to be administered = Weight of animal (g) X Dose of drug (mg/kg) 1000 X Concentration of drug (mg/ml) The remaining extract was stored in a refrigerator at a temperature of -4 degrees centigrade. Methods The rats were divided into six groups, each containing five animals. The basal blood glucose levels

of all the rats were obtained after fasting them overnight. This was done before they were injected with alloxan to make them diabetic. The purpose of this is to know their initial blood glucose level before the commencement of the experiment so as to compare the results of the basal blood glucose level when they are not diabetic with the Fasting Blood Sugar (FBS) level when they are made diabetic and this was done by using the glucometer. The procedure involved cutting a bit of their tails for a drop of blood and dropping this blood on a specified space on the glucometer. The FBS result was given in mg/dl. The rats in Groups 1 4 were injected with 100mg/kg alloxan intramuscularly and the Fasting Blood Sugar checked after 48hours.Those with FBS varying between 100 500 mg/dl were considered diabetic. These diabetic rats were then treated with 50mg/kg, 100mg/kg, 200mg/kg and 400mg/kg dose of the aqueous extract of Vernonia amygdalina twice daily respectively for two weeks. The administration was done orally with the aid of an oral cannula; the FBS was checked every two days and recorded. The animals in Group 5 were not given alloxan to induce DM but were administered with 400mg/kg of the plant extract of Vernonia amygdalina and their FBS were also recorded every two days for two weeks. The last group (Group 6) was left as the control of the experiment. They were neither induced with the drug alloxan nor were they administered with the plant extract. They were only fed with the commercial feeds and given clean water daily. Their FBS were also checked every two days and compared with the FBS of the other groups. The whole group of animals offered a commercial feed prepared by Ladokun Feed Mill Nigeria Ltd and the animals were given clean water everyday. Statistical Analysis The results are expressed as mean of five readings. The students t-test was utilized to determine the significance of differences between control and treated groups. The level of significance was taken as p< 0.05. Results and Discussion Table 1 shows the mean values of the fasting blood sugar levels in different groups. After the injection of alloxan, the mean fasting blood sugar levels of the groups of diabetic rats increased significantly because it rose from basal blood sugar levels (mg/dl) of 38.0, 39.2, 35.2 and 35.8 to fasting blood sugar levels (mg/dl) of 277.6, 284.8, 256.4 and 265.6 after the injection of alloxan. This effect was observed two days after the injection of alloxan in the rats. The mean values of FBS (mg/dl) of diabetic rats following the administration of different doses of Vernonia amygdalina in different groups of rats are as shown in Table 2. The results obtained revealed that there was a marked difference between the mean values of the FBS of group 1 which is 167.5mg/dl and the other groups. It took a longer period of time for the fasting blood sugar level of the rats administered with the plant extract Vernonia amygdalina to be reduced than it did for the rest of the other groups. Difference between the groups was significant (p < 0.05).

Results obtained in Table 3 revealed a significant decrease in the mean fasting blood glucose levels of the normal rats administered with 400mg/kg of Vernonia amygdalina which decreased from the mean fasting blood glucose level of 60.0mg/dl to 38.0mg/dl. This difference was statistically significant (p< 0.05). All the rats injected with the alloxan became diabetic as their fasting blood sugar levels exceeded the normal range of 80-100mg/dl. The mean values of the fasting blood sugar of the various groups of diabetic rats were reduced after they were given the plant extracts. Treatment of the rats with V amygdalina showed a dose dependent relationship with the period of time it took for the blood of the rats to return to the basal blood sugar levels (Table 2). The longest time was noticed in Group 1 rats (those treated with 50mg/kg which was longest than 14 days. This was followed by Groups 2 and 3 rats. The shortest time of return to the normal blood sugar was seen in the Group 4 rats (those treated with the highest dose - 400mg/ dl). It was observed that the blood glucose levels of the rats in group 1 reduced gradually and slowly as compared to the rats in the other groups and some of the rats were still diabetic after the experiment. It has been seen in this study that V amygdalina has hypoglycaemic activity. It has been observed that the dose of the plant extract administered affected the duration of time it took to treat the diabetic condition. Further work needs to be done to ascertain the appropriate dosage and duration of administration. Considering the great antidiabetic properties of the plant, awareness should be created to promote the medicinal advantages of the plant. REFERENCES Abosi, A. O. and Roseroka, B. H. 2003. In vivo anti malarial activity of Vernonia amygdalina Br J Biomed Sc. 60 (2): 89-91. Akinkugbe, O. O. 1992. Non-communicable diseases in Nigeria. Series I. Federal Ministry of Health and Human Services, Lagos. pp 23 25. Famuyiwa, O. O., Adenaike, F. A., Osotimehin, B. O. and Adetuyibi, A. A. 1988. Clinical study of diabetic nephropathy in Nigerian diabetic patients. Nig Med J 18 (1), 265-268. Izevbigie, E. B. 2003. Discovery of water soluble anticancer agents (edodites) from a vegetable found in Benin City, Nigeria. Exp Biol Med. 228 (3): 293-298. Kambizi, L. and Afolayan, A. J. 2001. An ethnobotanical study of plants used for the treatment of sexually transmitted diseases (njovhera) in Guruve District, Zimbabwe. J. Ethnopharmacol 77 (1) 5-9. Kings, H. and Rewers, W. 1999. Diabetes in adults is now a third world problem. Bulletin of the World Health Organization 69 (9), 643-648. Masaba, S. C. 2000. The anti malarial activity of Vernonia amygdalina. Trans Soc Trop Med Hyg 94 (6): 699-695. Taiwo, O., Xu, H. X. and Lee, S. F. 1999. Antibacterial activities of extracts from Nigerian chewing

sticks. Phytother Res. 13 (8): 675-679. Table 1. Mean values of the Fasting Blood Sugar (FBS ) levels in different groups. Group 1 Group 2 Group 3 Group 4 Basal Blood Sugar (mg/dl) 38.0 39.2 35.2 35.8 Fasting Blood Sugar after injection of alloxan (mg/dl) 277.6 284.8 256.4 265.6 Table 2. The mean values of Fasting Blood Sugar (mg/dl) in diabetic rats following the administration of different doses of V. amygdalina in different groups of rats. Alternate days Group 1 Group 2 Group 3 Group 4 that fasting blood (50mg/kg) (100mg/kg) (200mg/kg) (400mg/kg) sugar was obtained 2 nd 231.2 226.6 203.2 201.8 4th 237.4 200.0 151.6 94.0 6th 196.0 176.0 94.0 72.0 8th 163.4 132.0 89.0 62.0 10th 142.2 102.0 75.0 50.8 12th 110.4 80.0 61.0 44.0 14th 92.0 68.8 55.8 38.4 Mean FBS 167.5mg/dl 140.8mg/dl 104.2mg/dl 80.4mg/dl Table 3. The mean values of Fasting Blood Sugar (mg/dl) of the normal (Group 5) rats and the control (Group 6) group rats taken on alternate days.

Number of Days Normal Group Control Group administered with 400mg/kg of Vernonia amygdalina 2nd 60.0 44.0 4th 65.6 54.4 6th 54.4 46.0 8th 47.6 41.8 10th 42.2 41.0 12th 42.2 40.0 14th 38.0 40.0 Mean 50.0 43.9